According to MediWound's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.26337. At the end of 2022 the company had a P/E ratio of -3.48.
Year | P/E ratio | Change |
---|---|---|
2022 | -3.48 | -27.81% |
2021 | -4.82 | -57.04% |
2020 | -11.2 | -165.1% |
2019 | 17.2 | -116.97% |
2018 | -102 | 2135.28% |
2017 | -4.54 | -14.72% |
2016 | -5.32 | -36.41% |
2015 | -8.37 | 13.14% |
2014 | -7.40 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.